Unicycive Therapeutics, Inc. Logo

Unicycive Therapeutics, Inc.

A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.

UNCY | US

Overview

Corporate Details

ISIN(s):
US90460M2044 (+1 more)
LEI:
Country:
United States of America
Address:
4300 EL CAMINO REAL, SUITE 210, 94022 LOS ALTOS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2016, dedicated to developing and commercializing novel treatments for kidney diseases. The company focuses on identifying overlooked opportunities and addressing unmet medical needs for patients with renal conditions. Its lead investigational treatment is oxylanthanum carbonate (OLC). Unicycive utilizes an agile development process, leveraging its team's expertise to efficiently advance promising technologies into commercial therapies for patients in need.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Unicycive Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Unicycive Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Unicycive Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea
260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea
014570
Korro Bio, Inc. Logo
A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.
United States of America
KRRO
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan
4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan
4884
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia
KRKG
Krystal Biotech, Inc. Logo
Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.
United States of America
KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd Logo
A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.
South Korea
307750
Kura Oncology, Inc. Logo
Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.
United States of America
KURA
KWANGDONG PHARMACEUTICAL CO.,LTD Logo
Developing drugs & health goods by integrating oriental and Western medicine.
South Korea
009290

Talk to a Data Expert

Have a question? We'll get back to you promptly.